Thrombopoietin mimetics

Patent Number: 7,241,783

Thrombopenia, induced by chemotherapy, malignancy or radiotherapy is a substantial clinical problem. Protein therapeutics such as G-CSF have been developed and clinically implimented to deal with leukopenia. Similarly, thrombopoietin is under development as a treatment for thrombopenia. Unfortunately, various characteristics of the whole protein make it not an optimal treatment. The current patent covers the composition of matter for thiosemicarbazone derivatives that activate the thrombopoietin receptor. Such receptor mimetics are more attractive in comparison to protein therapeutics since they are easier to make and have better pharmacokinetics.

View this patent on the USPTO website.